CJC-1295 vs Argireline
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Argireline |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. |
| Best For |
What They Have in Common
Both CJC-1295 and Argireline are commonly used for: